Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation

被引：0
作者：
Niwa N. [1 ]
Watanabe E. [2 ]
Hamaguchi M. [1 ]
Kodera Y. [1 ]
Miyazaki H. [2 ]
Kodama I. [3 ]
Ohono M. [1 ]
机构：
[1] Departments of Cardiology and Hematology, Japanese Red Cross Nagoya First Hospital
[2] Divisions of Cardiology and Hematology, Department of Internal Medicine, Fujita Health University, Toyoake, 470-1192, 1-98 Dengakugakubo, Kutsukake-cho
[3] Department of Circulation, Research Institute of Environmental Medicine, Nagoya University
来源：
Annals of Hematology | 2001年 / 80卷 / 8期
关键词：
Cytokine; Diastolic function; Echocardiography; Heart failure; Radionuclide ventriculography;
D O I：
10.1007/s002770100331
中图分类号：
学科分类号：
摘要：
Clinical usefulness of bone marrow transplantation (BMT) remains limited by myocardial damage during the post-transplantation period. Measurements of plasma atrial and brain natriuretic peptides (ANP, BNP) during the acute post-transplantation period could serve to monitor cardiac complications since these peptides are known to increase in heart failure depending on its severity. We prospectively analyzed ANP and BNP levels from 14 days before to 100 days after BMT in 46 consecutive patients undergoing allogeneic (n=42) and autologous (n=4) transplantation. Cardiac performance was assessed by echocardiography and radionuclide ventriculography. BNP and ANP levels of the patients on admission (baseline: day-14) were 16.3±13.3 pg/ml and 14.4±8.8 pg/ml, respectively. There were two different types of changes in the BNP and ANP levels. The 21 patients in group I showed dual peaks of elevation on day 1 (BNP=164.4±136.0 pg/ml, P<0.01; ANP=44.5± 35.4 pg/ml, NS) and day 14 (BNP=233.9±106.2 pg/ml, P<0.01; ANP=142.7±154.6 pg/ml, P<0.05), whereas the remaining 25 patients in group II had a single peak on day 1 (BNP=124.5±124.9 pg/ml, P<0.05; ANP=45.2±42.4 pg/ml, NS). The left ventricular ejection fraction on day 63 was unchanged in both groups of patients from the baselines. The time to peak filling rate, a parameter of diastolic function in the radionuclide ventriculography, was significantly prolonged in group I patients (by 30±53%), whereas unaffected in group II patients. These results suggest that plasma BNP monitoring for 2 weeks after BMT may be useful for early detection of patients at high risk for cardiac dysfunction in the post-transplantation period.
引用
收藏
页码：460 / 465
页数：5
相关论文
共 21 条
  • [1] Thomas E.D., Marrow transplantation for malignant diseases, J Clin Oncol, 1, pp. 517-531, (1983)
  • [2] O'Reilly R.J., Allogenic bone marrow transplantation: Current status and future directions, Blood, 62, pp. 941-964, (1983)
  • [3] Eames G.M., Crosson J., Steinberger J., Steinbuch M., Krabill K., Bass J., Ramsay N.K.C., Neglia J.P., Cardiovascular function in children following bone marrow transplant: A cross-sectional study, Bone Marrow Transplant, 19, pp. 61-66, (1997)
  • [4] Lele S.S., Durrant S.T.S., Atherton J.J., Moore T.D., Thompson H.L., Khafagi F.A., Frenneaux M.P., Demonstration of late cardiotoxicity following bone marrow transplantation by assessment of exercise diastolic filling characteristics, Bone Marrow Transplant, 17, pp. 1113-1118, (1996)
  • [5] Pihkala J., Saarine U.M., Lundstom U., Salmo M., Virkola K., Virtanen K., Siimes M., Pesonen E., Effects of bone marrow transplantation on myocardial function in children, Bone Marrow Transplant, 13, pp. 149-155, (1994)
  • [6] Kupari M., Volin L., Suokas A., Timonen T., Hekali P., Ruutu T., Cardiac involvement in bone marrow transplantation: Electrocardiographic changes, arrhythmias, heart failure and autopsy findings, Bone Marrow Transplant, 5, pp. 91-98, (1990)
  • [7] Cazin B., Gorin N.C., Laporte J., Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive patients, Cancer, 57, pp. 2061-2069, (1986)
  • [8] Hertenstein B., Stefanic M., Schmeiser T., Scholz M., Goller V., Clausen M., Bunjes D., Wiesneth M., Novotomy J., Kochs M., Adam W., Heimpel H., Arnold R., Cardiac toxicity of bone marrow transplantation: Predictive value of cardiologic evaluation before transplant, J Clin Oncol, 12, pp. 998-1004, (1994)
  • [9] Goldberg M.A., Antin J.H., Guinan E.C., Rappeport J.M., Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor, Blood, 68, pp. 1114-1118, (1986)
  • [10] Gottdiener J.S., Appelbaum F.R., Ferrans V.J., Deisseroth A., Ziegler J., Cardiotoxicity associated with high-dose cyclophosphamide therapy, Arch Intern Med, 141, pp. 758-763, (1981)
123